Phase 3 Alopecia Areata Trial, Recruiting NCT07023302 Sponsor: AbbVie Condition: Alopecia Areata
Back to Alopecia Areata

Phase 3 Alopecia Areata Trial, Recruiting

NCT07023302
Recruiting Phase 3

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • The trial doctor has reviewed your health history and screening results and considers you to be in good health.
  • You have been diagnosed with severe alopecia areata (a condition causing significant hair loss) with at least 25% of your scalp hair lost, confirmed at both your screening and baseline appointments.
  • Your current episode of alopecia areata started less than 8 years ago.

Who may not be able to join:

  • You have been diagnosed with a diffuse type of alopecia areata (where hair loss is spread evenly across the scalp rather than in patches).
  • You have another type of hair loss condition — such as male or female pattern baldness (at a certain level of severity), traction alopecia, or several other specific scalp conditions — that could affect how the trial results are measured (confirm with trial site if unsure which conditions apply to you).
  • You have another inflammatory condition affecting your scalp, eyebrows, or eyelashes — such as seborrheic dermatitis, scalp psoriasis, eczema, or a fungal scalp infection — that could affect how the trial results are measured.
  • You have had an active infection requiring treatment through a drip (IV) within the last 30 days, or by mouth or injection within the last 14 days before your baseline appointment.
  • You have a long-term recurring infection or an ongoing viral infection that the trial doctor believes makes it unsafe for you to participate.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: ABBVIE INC., AbbVie

Phone: 844-663-3742

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 3
Sponsor
Registry
ClinicalTrials.gov
Start date
19 June 2025
Est. completion
1 February 2029

Where this trial is recruiting

🇯🇵 Japan

Primary endpoints

Percentage of Participants with the Achievement of Severity of Alopecia Tool (SALT) Score <= 10; Number of Participants with Adverse Events (AEs)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov